General Information of Drug (ID: DMUPEJK)

Drug Name
D-4418 Drug Info
Synonyms UNII-24A61J8R9E; D-4418; 257892-34-5; 24A61J8R9E; SCHEMBL450642; 5-Quinolinecarboxamide, N-(2,5-dichloro-3-pyridinyl)-8-methoxy-
Indication
Disease Entry ICD 11 Status REF
Cutaneous T-cell lymphoma 2B01 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9928260
CAS Number
CAS 257892-34-5
TTD Drug ID
DMUPEJK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Papaverine DMCA9QP Brain ischaemia 8B1Z Approved [3]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [4]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [5]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [6]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [7]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [8]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [5]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [9]
AWD-12-281 DMVADGZ Rhinitis FA20 Phase 2 [10]
LIRIMILAST DMD4KAU Chronic obstructive pulmonary disease CA22 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [4]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [11]
BI 1015550 DM6DO2P Idiopathic pulmonary fibrosis CB03.4 Phase 3 [12]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [6]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [7]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [8]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [11]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [13]
AWD-12-281 DMVADGZ Rhinitis FA20 Phase 2 [10]
LIRIMILAST DMD4KAU Chronic obstructive pulmonary disease CA22 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dyphylline DM8DZC1 Acute bronchial asthma CA23 Approved [14]
Enprofylline DMFYZKN Asthma CA23 Approved [15]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [4]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [16]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [17]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [6]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [7]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [8]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [16]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [2]
Phosphodiesterase 4B (PDE4B) TTVIAT9 PDE4B_HUMAN Inhibitor [2]
Phosphodiesterase 4D (PDE4D) TTSKMI8 PDE4D_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007757)
2 Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90.
3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4 Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
6 An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
7 Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
8 Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
10 The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
12 BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Apr 20;13:838449.
13 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
14 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
15 Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
17 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
18 GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.